{
  "id": 16059348,
  "title": "AbbVie notches Phase 3 win in painful skin condition, FDA filing likely next year",
  "url": "https://urgent.news/2026/10/22/abbvie-notches-phase-3-win-in-painful-skin-condition-fda-filing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-22T14:09:51.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/abbvie-notches-phase-3-win-in-painful-skin-condition-fda-filing-likely-next-year/"
  },
  "original_language": "en",
  "account": null,
  "summary": "AbbVie unwrapped a Phase 3 success on Thursday for an experimental drug designed to treat a debilitating skin disease. In the trial, AbbVie’s IL-1α and IL-1β inhibitor lutikizumab improved patient response ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}